208 related articles for article (PubMed ID: 6234371)
21. Immunization of DBA/2 mice with a T cell hybridoma-derived TsF increases immune resistance to the syngeneic tumors P815 and L1210.
Steele JK; Singhai R; Stammers AT; Levy JG
J Immunol; 1986 Nov; 137(9):3025-30. PubMed ID: 3489783
[TBL] [Abstract][Full Text] [Related]
22. Enhanced suppressor macrophage activity associated with termination of the L5178Y cell tumor-dormant state in DBA/2 mice.
Robinson MK; Truitt GA; Okayasu T; Wheelock EF
Cancer Res; 1983 Dec; 43(12 Pt 1):5831-6. PubMed ID: 6227383
[TBL] [Abstract][Full Text] [Related]
23. Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumor bearing mice.
Maas RA; Becker MJ; Weimar IS; De Nooy JC; Dullens HF; Den Otter WD
Immunobiology; 1993 Jul; 188(3):281-92. PubMed ID: 7901148
[TBL] [Abstract][Full Text] [Related]
24. Murine splenocyte migration inhibition assay I. Detection of differential responses to murine leukemia P388 and its adriamycin-resistant subline P388/ADR.
Nori M; Gothoskar BP
Neoplasma; 1983; 30(3):287-93. PubMed ID: 6223231
[TBL] [Abstract][Full Text] [Related]
25. Production of tumor-specific suppressor T cell hybridomas.
Bear HD
J Surg Res; 1987 Apr; 42(4):369-76. PubMed ID: 2437390
[TBL] [Abstract][Full Text] [Related]
26. Adoptive immunization against an established tumor with cytolytic versus memory T cells. Immediate versus delayed onset of regression.
Dye ES; North RJ
Transplantation; 1984 Jun; 37(6):600-5. PubMed ID: 6427998
[TBL] [Abstract][Full Text] [Related]
27. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.
Rakhmilevich AL; Buhtoiarov IN; Malkovsky M; Sondel PM
Cancer Immunol Immunother; 2008 Aug; 57(8):1151-60. PubMed ID: 18214476
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule.
La Motte RN; Rubin MA; Barr E; Leiden JM; Bluestone JA; Mokyr MB
Cancer Immunol Immunother; 1996 Mar; 42(3):161-9. PubMed ID: 8640844
[TBL] [Abstract][Full Text] [Related]
29. Adoptive immunotherapy of intracerebral murine lymphomas: role of different lymphoid populations.
Romani L; Nardelli B; Bianchi R; Puccetti P; Mage M; Fioretti MC
Int J Cancer; 1985 May; 35(5):659-65. PubMed ID: 3888855
[TBL] [Abstract][Full Text] [Related]
30. Application of Candida solubilized cell wall beta-glucan in antitumor immunotherapy against P815 mastocytoma in mice.
Tokunaka K; Ohno N; Adachi Y; Miura NN; Yadomae T
Int Immunopharmacol; 2002 Jan; 2(1):59-67. PubMed ID: 11789670
[TBL] [Abstract][Full Text] [Related]
31. Cytogenetic analysis of an immunogenic mutant of the L5178Y lymphoma.
Greenberg AH; Manougian J; Ray M; Goldenberg GJ
Acta Cytol; 1980; 24(3):232-6. PubMed ID: 6773281
[TBL] [Abstract][Full Text] [Related]
32. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
[TBL] [Abstract][Full Text] [Related]
33. Establishment and control of the L5178Y-cell tumor dormant state in DBA/2 mice.
Wheelock EF; Robinson MK; Truitt GA
Cancer Metastasis Rev; 1982; 1(1):29-44. PubMed ID: 6985247
[TBL] [Abstract][Full Text] [Related]
34. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
[TBL] [Abstract][Full Text] [Related]
35. Characterization of L5178Y cell phenotypes isolated during progression of the tumor-dormant state in DBA2 mice.
Trainer DL; Wheelock EF
Cancer Res; 1984 Jul; 44(7):2897-906. PubMed ID: 6609767
[TBL] [Abstract][Full Text] [Related]
36. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
Bear HD
Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451
[TBL] [Abstract][Full Text] [Related]
37. Effect of advanced aging on ability of mice to cause regression of an immunogenic lymphoma in response to immunotherapy based on depletion of suppressor T cells.
Dunn PL; North RJ
Cancer Immunol Immunother; 1991; 33(6):421-3. PubMed ID: 1878896
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells.
Streilein JW; Niederkorn JY
J Immunol; 1985 Mar; 134(3):1381-7. PubMed ID: 3155766
[TBL] [Abstract][Full Text] [Related]
39. Specific tumoricidal activity of cytotoxic macrophages and cytotoxic lymphocytes.
Dullens HF; Schakenraad S; Oostdijk A; Vuist W; Van der Maas M; Den Otter W
Cancer Immunol Immunother; 1986; 22(2):100-6. PubMed ID: 3487380
[TBL] [Abstract][Full Text] [Related]
40. Adoptive immunotherapy is suppressed in C57BL/6J and B6.C-H-2bm12 mice following recognition of congenic class II MHC antigen determinants.
Evans R; Duffy TM
Int J Cancer; 1989 Nov; 44(5):854-8. PubMed ID: 2479606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
